Inmune Stock News

INmune Bio is focused on developing drugs for neurology and cancer medicine. The company's most advanced product candidate is XPro 1595, which is being developed for Alzheimer's disease. INMB's financ

INmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript

Boca Raton, Florida, Feb. 06, 2024 (GLOBE NEWSWIRE) --   INmune Bio, Inc.   (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammat

Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of

Generally speaking, earnings losers represent exactly that – companies that failed to deliver against established targets. Just like in sports, you don't get points for missing the shot or not going

INmune Bio, Inc. (NASDAQ:INMB ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants David Moss - Chief Financial Officer RJ Tesi - Chief Executive Officer Mark Lowdell -

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage im

Analysts at Baird initiated coverage of the immunology company INmune Bio with a price target more than double its current share price.  The firm issued an Outperform rating and target price of $16.

BOCA RATON, Fla., May 24, 2023 (GLOBE NEWSWIRE) --   INmune Bio Inc. (NASDAQ: INMB) announces that Mark Lowdell, Ph.D., INmune Bio's CSO, will be giving the opening plenary lecture of the Presidentia

INmune Bio, Inc. (NASDAQ:INMB ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants David Moss - Chief Financial Officer RJ Tesi - Chief Executive Officer Mark Lowdell - Chief

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April 24, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage i

INmune Bio: Alzheimer's Disease Treatment Lottery Ticket.

Two presentations show targeting high-risk MUC4 expressing HER2+ and Triple Negative Breast Cancer with INB03 reverses resistance mechanisms to immunotherapy

INmune Bio, Inc. (NASDAQ:INMB ) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants David Moss - CFO RJ Tesi - CEO CJ Barnum - Head of Neuroscience Mark Lowdell - Chief Scie

Management to host conference call and webcast at 4:30 pm ET on that day